News for Novo Nordisk A/S (0TDD.L)

As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading d...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today announces a €14,999,998.59 capital increase

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

(Bloomberg) -- US stocks are set to bounce back from Monday’s losses as investors nervously weighed up progress on trade talks with India and Tesla Inc.’s upcoming earnings. Gold topped $3,500 for the first time.Most Read from BloombergDOGE Visits National Gallery of Art to Discuss Museum’s Legal StatusTrump Gives New York ‘One Last Chance’ to End Congestion FeeTrump Administration Takes Over New York Penn Station RevampThe Racial Wealth Gap Is Not Just About MoneyNashville’s $3 Billion Transit

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 currently.

Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations.

To gain an edge, this is what you need to know today. Avoid The Common Investment Mistake Please click here for an enlarged chart of iShares 20+ Year Treasury...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discussed recently. On Friday, Mad Money host Jim Cramer addressed growing concerns in the market as tensions between the […]

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO.

MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. ( VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines fo

\nStrong focus on diabetes care and obesity treatment, driving revenue growth.Leading market position in insulin and GLP-1 receptor agonists.Potential risks incl

Pharmaceutical giant Pfizer stopped development of its weight-loss pill, danuglipron, after it discovered that one patient suffered potential liver issues.

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo Nordisk A/S (NVO) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks Genie Energy Ltd. (GNE) and Canterbury Park Holding Corporation (CPHC).

Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best beaten down stocks to buy according to analysts. JPMorgan released a market update where it highlighted the US Fed’s […]

We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts.

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US equities experienced significant gains in Q4, showcasing a strong year. The portfolio showed slight weakness in Q4 but posted a strong absolute return in 2024. In the fourth […]